Vorapaxar, Combination Antiplatelet Therapy, and Stroke∗
نویسندگان
چکیده
منابع مشابه
Vorapaxar, combination antiplatelet therapy, and stroke.
SEE PAGES 2309 AND 2318 D rugs that inhibit platelet activation and aggregation reduce vascular events, notably myocardial infarction (MI) and ischemic stroke, and are generally associated with low rates of bleeding (1). Available agents inhibit platelets via distinct mechanisms (Table 1) (2), and combining antiplatelet drugs with different mechanisms of action should enhance net antithrombotic...
متن کاملVorapaxar expands antiplatelet options.
Vorapaxar is the first substance of a new class of antiplatelet drugs that has been tested in large clinical trials. The protease-activated receptor 1 (PAR-1) antagonist inhibits thrombin-induced platelet activation to prevent atherothrombosis. In the phase 3 trials TRACER (acute coronary syndrome) and TRA 2P-TIMI 50 (stable atherosclerosis) reducing ischemic events with vorapaxar came at the c...
متن کاملVorapaxar: targeting a novel antiplatelet pathway.
564 P&T® • September 2011 • Vol. 36 No. 9 INTRODUCTION In the setting of non–ST-segment elevation acute coronary syndromes (NSTE ACS), optimal management includes multitiered antithrombotic therapy. Acute and postcardiac-event antithrombotic management is focused on the central role platelets play in thrombosis. Platelets can be activated by a number of different agonists, including thromboxane...
متن کاملCombination antiplatelet therapy: implications for pharmacists.
OBJECTIVES To present two case reports of patients who received suboptimal oral antiplatelet therapy and to review recent changes in national guidelines for management of acute coronary syndromes. DATA SOURCES Personal observation by the authors, and clinical practice guidelines and related clinical trials of the American Heart Association and the American College of Cardiology. SUMMARY The...
متن کاملStroke Prevention: Update on Antiplatelet Therapy
PRIMARY STROKE PREVENTION Primary stroke prevention requires a comprehensive multidisciplinary approach. The first objective is to identify and modify stroke risk factors, including hypertension; diabetes mellitus; myocardial infarction (MI); hyperlipidemia; atrial fibrillation; asymptomatic carotid stenosis; and lifestyle factors, such as smoking, alcohol use, and sedentary lifestyle.3 In addi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2014
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2014.09.038